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Abstract
The recent advances in sequencing technologies have given all microbiology laboratories access to whole genome sequencing. Providing that
tools for the automated analysis of sequence data and databases for associatedmeta-data are developed, whole genome sequencingwill become
a routine tool for large clinicalmicrobiology laboratories. Indeed, the continuing reduction in sequencing costs and the shortening of the ‘time to
result’ makes it an attractive strategy in both research and diagnostics. Here, we review how high-throughput sequencing is revolutionizing
clinical microbiology and the promise that it still holds.We discuss major applications, which include: (i) identiﬁcation of target DNA sequences
and antigens to rapidly develop diagnostic tools; (ii) precise strain identiﬁcation for epidemiological typing and pathogen monitoring during
outbreaks; and (iii) investigation of strain properties, such as the presence of antibiotic resistance or virulence factors. In addition, recent
developments in comparative metagenomics and single-cell sequencing offer the prospect of a better understanding of complex microbial
communities at the global and individual levels, providing a new perspective for understanding host–pathogen interactions. Being a high-
resolution tool, high-throughput sequencing will increasingly inﬂuence diagnostics, epidemiology, risk management, and patient care.
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Introduction
In recent years, there has been a major transformation in the
way that clinicians and researchers extract genomic information
from patient samples. The development of ultra-high-throughput
sequencing (UHTS) technologies has been instrumental in
advancing research in all scientiﬁc areas, but particularly in
microbiology, where genomes are small. As shown by the
impressive increase in genomic data output (Fig. 1), whole
genome sequencing (WGS) has entered all research laborato-
ries, and will soon become an integrated tool in diagnostic
laboratories.
In clinical bacteriology, it is critical to rapidly characterize
the pathogen present in a clinical sample, to improve patient
care. Identiﬁcation at the species level and antibiotic suscep-
tibility testing are of major importance in guiding antibiotic
treatment and the management of infectious diseases.
Although matrix-assisted laser desorption ionization time-of-
ﬂight (MALDI-TOF) mass spectrometry (MS) has been a
revolution in clinical microbiology, and may have signiﬁcant
applications in typing, identiﬁcation, and even toxin detection
[1], there is still no high-throughput approach with which to
fully and rapidly characterize any bacterial strain. Generally,
such detailed characterizations involved multiple analyses, and
were only performed by research laboratories specializing in a
given pathogen. These detailed analyses take days to months,
depending on the type of bacterium and the complexity of the
question.
UHTS offers the possibilities of reducing the number of
steps needed for full characterization of the pathogen, and
optimizing the ‘time to result’ (Fig. 2). Bacterial whole genome
shotgun sequence data can be obtained from a pure culture,
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directly from a clinical sample, or even from a single bacterium
present in a given sample [2,3]. Genome ﬁnishing—the most
costly and time-consuming step—is often not necessary, and
the release of unﬁnished genomes has become a major trend in
the area [4,5]. Unﬁnished genomes, also called raw, draft or
dirty genomes, provide enough data for extraction of the
required information (Fig. 3), such as the presence of toxins
[6] or genes or mutations coding for antibiotic resistance [7].
Unﬁnished genomes can also be directly used to develop new
diagnostic tests such as ELISA [4] and PCR [8].
WGS has become rapid and cheap enough to replace some
older techniques previously used to characterize a pathogen at
the genomic level. We review here the main UHTS techniques,
and discuss their main applications in clinical and diagnostic
laboratories. Finally, we highlight substantial challenges that
remain in the development of innovative pipelines for genome
analysis and data storage, to gather information in an effective,
accurate and harmonized way.
Sequencing Technologies—in Short
In 2005, new high-throughput sequencing technologies
appeared on the market, and were referred to as ‘next-
generation sequencing’ technologies, as they replaced Sanger’s
dideoxy chain termination sequencing method. Their develop-
ment was quick and remarkable, and they rapidly turned out to
be essential tools for microbial genomics. Next-generation
sequencing technologies have been the subject of excellent
reviews [9,10], and we will only highlight their main advantages
and limitations with regard to their use in clinical microbiology
(Table 1).
The 454 Genome Sequencer, the ﬁrst to be commercialized,
rapidly established itself as a standard for de novo sequencing
and metagenomics, thanks to its long reads (up to 700 bp) [11].
Shortly thereafter, Solexa sequencing by synthesis became the
most widely used system among the research community [12].
It has major applications in resequencing and RNA sequencing,
thanks to its high throughput, allowing a lower cost per base,
although with shorter reads (36–150 bp). The SOLiD sequenc-
ing system [13], based on two-base sequencing by ligation, is
insensible to homopolymer errors, and is principally used for
resequencing, transcriptomics, or epigenomics. Arriving later in
the ﬁeld, Heliscope [14] remained marginally used by the
community. Both 454 and Solexa offer the possibility of
obtaining paired-read information, which is of great help for
assembly. In addition, samples can easily be tagged with short
(6–8 bp) barcoding sequences and pooled into a single run.
Finally, thanks to its higher throughput, Illumina enables the
multiplexing and sequencing of nearly 100 bacterial samples at a
time, making it a cost-effective platform for sequencing large
collections of bacteria.
More recently, a third generation of technologies arrived on
the market. Life Science launched the Ion Torrent PGM and
the Ion Proton Sequencer, which are based on the sensing of
proton release during base incorporation [15]. The major
FIG. 1. Milestones in whole genome sequencing. The number of complete and draft genomes from the Archaea (n = 172), Bacteria (n = 3625) and
Eukarya (n = 183) deposited in public databases from 1995 to 2012 is shown, as extracted from the GOLD database (www.genomesonline.org/) in
December 2012. The advent of high-throughput sequencing led to a rapid increase in the number of complete genome sequences (green), but the
short read length, in particular, triggered the ﬁnal publication of draft genome sequences (orange). EHEC, enterohaemorrhagic Escherichia coli.
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advantage of this technology is the short run time, enabling
sequences to be obtained in only a few hours vs. several days
for previous high-throughput sequencers. Finally, biology-
based systems, such as PacBio and Nanopore, directly
sequence DNA at the single-molecule level, respectively by
detecting the ﬂuorescence of dye-labelled nucleotides added
by an immobilized polymerase [16], or by sensing the ionic
current of DNA that passes through a pore [17]. They both
yield very long reads, which should facilitate the mapping and
assembly of repeated and complex DNA.
The various systems have different characteristics, prevent-
ing the development of a universal approach for data analysis.
(a)
(b)
FIG. 2. Processing of clinical samples in the diagnostic laboratory: schematic representation of the timeline for the processing of clinical samples
with classical pathogens (a) or slow-growing bacteria such as Mycobacterium tuberculosis (b). Clinical samples are directly submitted for antigen
detection (immune chromatography), PCRs, Gram stain and/or serology while the bacterium is being cultured. Once a pure bacterial culture is
obtained (red star), a second panel of analyses is performed. Direct sequencing on clinical sample allows shortening of the ‘time to result’ (red dashed
arrow), especially for fastidious bacteria or slow-growing bacteria. Techniques are coloured according to their application for bacterial detection
(yellow), species identiﬁcation (green), antibiotic susceptibility testing (pink), and strain typing (orange). The main steps of genome sequencing are
highlighted in purple. MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry; MLST, multilocus sequence
typing; PFGE, pulsed-ﬁeld gel electrophoresis; POCT, point-of-care tests; RFLP, restriction fragment length polymorphism.
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Software developers face challenges to cope with the
increasing number of reads and to integrate their particular
characteristics in terms of length, type of error, error rate and
particular weak points. Whereas 454 and Ion Torrent are
more prone to artiﬁcial insertions or deletions in long
mononucleotide repeats, Solexa and PacBio result in more
substitution errors. In addition, 454, Solexa, SOLiD, Heliscope
and Ion Torrent are based on a ﬁrst PCR ampliﬁcation step
that results in biased sequence representation, artiﬁcially
generating deep-coverage or low-coverage regions. Even
though PacBio and Nanopore avoid this bias, these technol-
ogies are still young, and may also have other drawbacks, such
as the error rate, which is notably high.
Applications
In diagnostic bacteriology, the processing of clinical samples
has changed little over the years, and most analyses still
depend on isolating a viable microorganism (Fig. 2), although
antigen detection and PCR have been strongly developed in
recent years, allowing faster diagnosis as well as accurate
detection of fastidious organisms, strict intracellular bacteria,
and viruses. The clinical applications of genomics can be
divided into two categories: (i) those requiring a bacterial
isolate, such as bacterial typing, outbreak monitoring, or the
determination of biological properties, such as the presence of
virulence factors; and (ii) others that may be applied directly
on the sample, such as metagenomics and community proﬁling.
The future of clinical microbiology certainly lies in the
development of methods to obtain full microbial genomes by
the direct sequencing of clinical samples. This strategy was
successfully applied to sequence the eukaryote Plasmodium
falciparum from a blood cell-depleted sample of blood [18], and
the bioterrorism agent Francisella tularensis from abscess pus
[19]. Direct sequencing could be applied to physiologically
sterile samples or to samples with high bacterial concentra-
tions (millions of copies/mL). If required, the bacterial
concentration could be increased by using an initial antibody-
based bacterial puriﬁcation step. Direct sample sequencing
FIG. 3. Dirty genome vs. full genome: comparison of the dirty
genome of Parachlamydia acanthamoebae Hall’s coccus with the full
genome of P. acanthamoebae UV7 highlights the completeness of draft
assemblies. The missing genomic segments in the draft assembly are
shown in white (inner circle), and account for only 6% of the 3-Mbp
genome. In addition, some differences may be intrinsic true biological
differences between the two bacterial strains, and the proportion of
missing genomic DNA is thus overestimated. Genes of P. acanthamoe-
bae UV7 encoded on the plus and minus strands are depicted in the
two outermost circles.
TABLE 1. Main sequencing technologies and their characteristics
Technology
(manufacturer) Sequencing chemistry Platform
Read length
(bp)
Throughput (Gb/h
run) Best suited for:
Sanger Dye terminator ABI 3730xl 700–900 De novo and
metagenomics
454 (Roche) Pyrosequencing GS FLX 400–700 0.04 De novo and
metagenomics
GS Junior 400 0.004 De novo and
metagenomics
Solexa (Illumina) Sequencing by synthesis with reversible
terminators
GaIIx 36–150 0.3 Resequencing
HiSeq2000 36–100 2.9 Resequencing
MiSeq 36–250 0.2 Resequencing
SOLiD (ABI) Sequencing by ligation 5500xl 35–75 1 Resequencing
Heliscope (Helicos) Sequencing by synthesis with virtual
terminators
tSMS 25–55 1 Resequencing
Ion Torrent (Life
Technologies)
Semiconductor sequencing Ion torrent PGM 100–200 0.2 Resequencing
Ion proton
sequencer
100–200 2.5 Resequencing
PacBio (Paciﬁc Bioscience) SMRT technology PacBioRS 250–10 000 0.1 Genome structure and
metagenomics
Nanopore (Oxford
Nanopore Technologies)
Ionic current sensing GridION and
MinION
10 000–50 000* * De novo and genome
structure
*Data not available on the corporate website.
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provides major advantages, as it permits a gain in time
equivalent to the time needed for bacterial culture, and also
allows the detection of unculturable bacteria.
Diagnostics, species identiﬁcation, and taxogenomics
Determining the bacterial species is often crucial for making
accurate clinical decisions, and it provides direct information
on pathogenic potential. Historically, bacterial identiﬁcation
was based principally on colony growth time and morphology,
Gram staining, sugar assimilation/fermentation, and biochem-
ical tests. MALDI-TOF MS has recently been introduced
successfully for routine use [1], thanks to its rapid turn-
around time (minutes) and very low running cost. However,
MALDI-TOF MS fails to identify unusual species in approxi-
mately 50% of cases [20]. These species may then be identiﬁed
by sequencing of a few phylogenetically informative core genes,
such as 16S rRNA or rpoB. In rare situations, when precise
classiﬁcation of novel species to a new clade is required, dirty
genome sequencing might be useful for helping with species
description.
Genome sequences have been widely used to develop new
diagnostic tests for known pathogens [21,22] and emerging
pathogens such as Tropheryma whipplei [23], or mutant variants
such as Chlamydia trachomatis harbouring a deletion on its
cryptic plasmid [24]. Furthermore, raw genome sequences
may help in identifying new targets for diagnostic PCRs or for
the development of serological tests, e.g. ELISA [4]. An
interesting initiative was the establishment of a webserver,
ssGeneFinder, that is able to provide gene targets for the
identiﬁcation of speciﬁc microorganisms based on automated
analysis of their pan-genome [25].
At present, species are deﬁned by both phenotypic and
genetic characteristics, and represented by type strains
deposited in two international strain collections. With the
advent of WGS, Didelot et al. [26] proposed that genomic
reference sequences should constitute a reference standard.
Newly sequenced microorganisms would then be classiﬁed
among all previously sequenced reference genomes by phylo-
genetic reconstructions. Nevertheless, we think that a poly-
phasic taxonomy that includes both phenotypic and
phylogenetic analyses is still needed.
Jolley et al. [27] proposed the use of multilocus sequence
typing (MLST) based on ribosomal protein-encoding genes to
classify the available 1900 bacterial genomes. These genes,
which are essential for the bacterial cell, have the advantage of
being present in all bacteria, as well as providing more
resolution than 16S rRNA, being under strong selection for
functional conservation. Any new genome could easily be
placed in the current classiﬁcation by analysis of the same 53
conserved ribosomal genes. In another study, Larsen et al. [28]
developed a web-based method for MLST based on preas-
sembled genomes or directly on short sequence reads. The
available MLST schemes based on various alleles are currently
restricted to 66 bacterial species, but cover the most
important pathogens.
With the increase in available sequences, such comparative
methods will improve statistical power and will be highly
discriminative, allowing a precise bacterial species classiﬁca-
tion. As comprehensive approaches, they certainly constitute a
major improvement over actual classiﬁcation cut-offs based on
DNA–DNA hybridization (>70%) [29], 16S rRNA identity
(>95%) [30], or average nucleotide identity [31]. However,
new ambiguities may be revealed, e.g. the apparent polyphyly
of Bacillus cereus and Bacillus thuringiensis [32] or Neisseria
polysaccharea [33]. Thus, they will challenge the deﬁnition of
bacterial species, and eventually lead to deep modiﬁcations of
the current taxonomy.
An ideal typing tool for epidemiology
The typing of bacterial strains is essential for investigating
transmission pathways and supporting the monitoring of
outbreaks. Some reference laboratories use restriction frag-
ment length polymorphism, pulsed-ﬁeld gel electrophoresis or
MLST to type bacterial strains. Until recently, these techniques
were considered to be reference standards for epidemiology,
but they have limited resolution in differentiating strains
evolving from a single bacterial clone [34–36].
WGS represents the ultimate tool in epidemiological typing,
as it allows the identiﬁcation of single genomic changes
between two isolates. With the advent of inexpensive high-
throughput sequencing, it is now becoming fast and cheap
enough to be widely used in routine epidemiological investi-
gations. The ﬁrst attempt to sequence a whole organism for
epidemiological investigation was made after the anthrax letter
attack in the USA in 2001. The whole genome of Bacillus
anthracis was determined by Sanger sequencing and compared
with other genotypes, and this indicated that the morpholog-
ical variants present in the letters were not prevalent in the
environment [37].
Multiple epidemiological studies are now exploiting the
single-nucleotide polymorphisms that differentiate strains to
investigate their relatedness by simple phylogenetic analyses.
Sanger and Illumina sequencing were applied to investigate the
spread of the leprosy agent, Mycobacterium leprae, through
human migration and trade routes [38]. When the resolution
is optimal, i.e. when the rate of genomic variation is sufﬁciently
high, it is even possible to determine the transmission route
between hospital centres or even between patients in the
same ward. For example, Harris et al. [39] used Illumina
sequencing to investigate the micro-evolution and propagation
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of a methicillin-resistant Staphyloccocus aureus strain through
ﬁve continents. McAdam et al. [40] performed Bayesian
phylogenetic reconstructions to identify the probable spread
of the pandemic EMRSA-16 clone from large hospital centres
to regional healthcare settings in UK. Similarly, Lewis et al. [41]
investigated the spread of a multidrug-resistant Acinetobacter
baumanii strain in a hospital outbreak by using 454 sequencing
technology. Recent studies on methicillin-resistant Staphylo-
ccocus aureus [42] and Clostridium difﬁcile [43,44] highlighted the
beneﬁt for healthcare of bench-top high-throughput sequenc-
ing strategies to detect outbreaks and person-to-person
transmission.
Until now, WGS has been of no help to doctors in ﬁghting
epidemics, owing to the delay in detecting the outbreak and
sequencing the strain. However, it was of great help in
determining the transmission route and gaining insights into
the history of pathogen spread. Moreover, as shown by the
German Escherichia coli outbreak (see below), WGS is key to
understanding the determinants and modelling the evolutionary
events that may lead to a hypervirulent strain. Thus, monitoring
and investigation of past and recent outbreaks is of particular
importance to improve our understanding of pathogen trans-
mission and our management of risk and crisis situations.
Pathogen monitoring during outbtreaks—the case of E. coli
O104:H4
The recent outbreak of the virulent E. coli O104:H4 is an
excellent illustration of the speed of data acquisition and major
outcomes that can be obtained by WGS (Fig. 4). In May 2011,
an outbreak of diarrhoea and haemolytic–uraemic syndrome
(HUS) caused by a Shiga toxin-producing E. coli strain started
in Germany. In 2 months, over 3100 non-HUS cases and 900
HUS cases were reported, causing 53 deaths. Several inde-
pendent centres rushed to sequence some outbreak and
historical reference isolates, most of them combining different
sequencing technologies [45–47]. Within <2 weeks from the
identiﬁed onset of the outbreak, and within <62 h from strain
isolation, the ﬁrst draft genomes were available and deposited
in public databases [45]. Rohde et al. [47] provided an
interesting approach in setting up an open-source genomics
program for the analysis of their strain.
Several studies reached the conclusion that the outbreak
was caused by the unusual E. coli serotype O104:H4, which
contained genes from both enteroaggregative E. coli (EAEC)
and enterohaemorrhagic E. coli (EHEC) [45–47]. Although it is
similar to EAEC, the outbreak clone harbours a prophage
encoding Shiga toxin, as well as additional virulence and
antibiotic resistance factors [45,46]. Mellman et al. [45]
suggested that a highly pathogenic hybrid of EAEC and
EHEC emerged by gain and loss of chromosomal and
plasmid-encoded factors. This story illustrates how the
plasticity of bacterial genomes with regard to genetic
exchanges can form new virulent pathogens and this multi-
centre work demonstrated the feasibility and usefulness of
rapid draft genome sequencing.
Biology and virulence
Genome sequences provide some information for virulence
determination, and open new prospects for large-scale
research on genotype–phenotype associations. In principle, it
is possible to predict resistance to antibiotics by identifying
known genetic elements, e.g. mecA, which confers methicillin
resistance to S. aureus [48], or drug targets such as rpoB and
others for Mycobacterium tuberculosis [49,50]. However, if full
genomes are excellent resources for identifying known
mechanisms of antibiotic resistance, susceptibility testing is
inexpensive and fast for rapid-growing bacteria, and also allows
the detection of resistance not associated with gene muta-
tions, such as decreased permeability of bacterial cell walls to
antibiotics. Furthermore, genetic systems for resistance may
be complex and are not necessarily well characterized, making
phenotypic–genotypic comparisons difﬁcult.
In this case, UHTS may only be used as a complement to
routine susceptibility testing to investigate abnormal results
and new mechanisms of resistance. Comparative genomics is a
strategic approach for investigating the resistome of bacterial
strains, and was successfully applied to A. baumanii [51] and
Burkholderia dolosa [52]. Similarly, comparing strains that have
become resistant after laboratory selection may provide
insights into the evolutionary mechanisms for the acquisition
of resistance, such as for Bacillus anthracis [53].
Likewise, many bacteria encode well-characterized toxins
that are known to cause severe diseases, such as HUS caused by
EHEC [54], toxic shock syndrome caused by Streptococcus
pyogenes [55], or diphtheria caused by Corynebacterium diphthe-
riae [56]. In this setting, full genome sequencing allows us to
conﬁrm the presence of toxins and to identify new or mutated
toxins that may be missed by diagnostic PCRs speciﬁcally
targeting toxin-encoding genes. During the recent outbreak of
cholera in Haiti, PacBio sequencing was used on a number of
strains to characterize the phage-encoded toxin [57].
Clinical metagenomics
The proﬁling of microbial communities was historically based
on the cloning and Sanger sequencing of 16S rRNA, followed
by phylogenetic analyses. This ﬁrst culture-free method
improved our knowledge of bacterial diversity [58]. Today,
high-throughput sequencing strategies have taken over,
avoiding the need for cloning, and providing good sensitivity
to rare DNA, thanks to their very high coverage [59,60].
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454 pyrosequencing rapidly appeared as a method of choice,
and was shown to reveal a greater variety of species and a give
more reliable estimate of their relative abundance, although it
has a tendency to inﬂate the estimates of microbial diversity
[61]. Dethlefsen et al. [62] pyrosequenced tagged hypervariable
regions of the 16S rRNA from the gut microbiome of patients
before and after ciproﬂoxacin treatment. The antibiotherapy
reduced the taxonomic diversity in the gut, and inﬂuenced the
abundance of one-third of bacterial taxa. Similarly, Armougom
et al. [63,64] showed the differences in microbial communities
in obese, normal and anorexic patients. Other studies reported
the use of Illumina-based sequencing to unravel the oral
microbiota [65] or the gut microbiota, for which over 3 million
non-redundant genes were characterized [66].
An interesting initiative is the Human Microbiome Project,
which was funded to characterize the microbiomes of 250
volunteers and to identify associations with potential diseases
[67]. As the project progressed, terabases of sequences were
released [68], and they provide a comprehensive picture of the
healthy human body microbiome [69] and its metabolome [70].
Recently, there was a proposal to use culturomics, i.e. the
use of a large panel of different culture conditions, as a
complement to metagenomics [71,72]. This approach led to
the identiﬁcation of new species, and showed only a partial
redundancy of both methods (<20%), with culturomics being
more sensitive and avoiding a certain amount of coverage bias,
and metagenomics allowing the detection of so-called uncul-
turable bacteria.
FIG. 4. The Escherichia coli O104:H4 epidemics: event timeline and major outputs. BD, bloody diarrhoea; HUS, haemolytic–uraemic syndrome;
HUSEC, enterohaemorrhagic E. coli associated with HUS. Adapted from Mellmann et al. [45].
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Single-cell genomics
The use of single-cell genomics is emerging as a new strategy
for the investigation of microbial communities and uncultured
microorganisms present in clinical samples [2,3]. The ampliﬁ-
cation of femtograms of bacterial DNA is based on a method
called multiple displacement ampliﬁcation [73,74], which
avoids the need for cultivation. Raghunathan et al. [75] ﬁrst
provided the proof-of-principle that DNA from a single
bacterium could be sequenced. Further technical improve-
ments in cell isolation and DNA ampliﬁcation, sequencing and
assembly have made it possible to assemble almost complete
genomes from single cells [76].
Single-cell sequencing has already provided draft genome
sequences of major bacterial taxa that were not previously
available in the databases. It has been used principally to
sequence environmental bacteria such as Beggiatoa [77] and
Poribacteria [78], but it has broad applications for clinical
investigations as well. As shown by Grindberg et al. [79], single-
cell sequencing can be efﬁciently combined with metagenomics
to provide an inventory of the microbial community and the
genetic linkage of sequences in a single organism. Their analysis
enabled discovery of the gene cluster required for the synthesis
of apratoxin, a promising cytotoxin for cancerous cells. Such
combined metagenomics–single-cell sequencing approaches
should provide a deeper understanding of human microbial
communities and target novel unculturable pathogens.
Challenges in the Pipeline
With the decrease in cost, high-throughput sequencing is now
available to a large number of diagnostic laboratories and
clinical research groups. The question is no longer when and
where to sequence, but how to rapidly transform genomic
data into biological and clinically useful knowledge. Although it
is easy to perform on a laboratory scale, the technique will
result in maximal beneﬁt to the scientiﬁc community only if a
global system for sharing genomic data and mining information
on microorganisms is created.
Indeed, clinicians and researchers need to not only assemble
the genome of the pathogen but also to interpret the data,
which requires the incorporation of a century of knowledge
into databases and the comparison of multiple strains. For
example, when the genome of Vibrio cholerae from the epidemic
in Haiti was sequenced, some evidence pointed to UN
peacekeepers importing it from Nepal [57]. However, it was
only after months that a strain from Nepal was analysed and the
link could be ultimately conﬁrmed [80].
Such information is currently delivered by a skilled work-
force, but the process needs to be automatized to allow mainly
computer-driven processing of genomes. In the ﬁrst stage,
global national servers will probably be preferred to store
pathogen information, resistance proﬁles, and disease details,
especially for pathogens considered to be possible bioterror-
ism agents. It is thus a challenge to create a global resource
from which the hundreds of thousands of genomes sequenced
annually and their associated so-called meta-data could be
provided to the whole scientiﬁc community. Such an effort
requires reinforcing collaboration and breaking down barriers
between doctors, biologists, and bioinformaticians. Ideally,
information should be shared between countries as soon as it
is available, and scientists should stop retaining information
until a paper is published. Finally, harmonization of procedures
for data sequencing and analysis will facilitate the comparison
and exchange of results obtained in different laboratories.
The Future of Genomics in Clinical
Microbiology
High-throughput sequencing is sweeping through clinical micro-
biology, every day bringing biological knowledge and novel ideas
for clinical applications of microbial genomics. Bacterial genom-
ics has proved to be an excellent tool for investigating strain
particularities that may explain atypical syndromes. In the near
future, investigations of unusual bacterial infection cases will
likely include a description of the corresponding bacterial
genome and the analysis of strain particularities. Similarly, UHTS
represents a high-resolution typing tool for epidemiology. The
recent epidemics of Shiga-toxin producing E. coli in Germany
demonstrated the role of genomics in the development of tools
for diagnosis and increasing our understanding of the dynamics
of bacterial origin and spread.
UHTS represents a milestone towards the simpliﬁcation of
bacterial diagnostic procedures and possibly toward single-
step analysis (Fig. 2). Indeed, the isolation of bacterial strains is
common to generations of microbiologists, but can be labour-
intensive, especially for some fastidious intracellular bacteria
and slow-growing species, despite increasing automation and a
variety of new chromogenic media that facilitate strain
isolation. Also, culture approaches remain of limited value
when a patient has been pretreated with antibiotics and is not
sensitive to unculturable bacteria. New developments that
avoid the need to ﬁrst culture the bacterium are welcome,
especially for slow-growing bacteria, as they enable signiﬁcant
gains in time (Fig. 2B).
Direct raw sequencing of clinical samples will become a
major asset, and may be used for diagnostics. Moreover, single-
cell sequencing promises to accelerate our understanding of
the vast numbers of microorganisms that affect our health.
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Although we have only begun to understand the microbial
diversity in healthy and unhealthy patients, we can clearly see
that detailed human microbiome analysis could become part of
routine patient clinical management.
It is increasingly appealing to not only consider investigating
the pathogen, but also to perform host genomics simulta-
neously, at least for bacteria whose pathogenicity has been
clearly associated with speciﬁc genetic susceptibilities, such as
T. whipplei [81], M. tuberculosis [82], or C. trachomatis [83]. The
principle of dual host–bacterium genomics may also be applied
to RNA sequencing to obtain a comprehensive view of changes
in gene expression in both interacting partners [84].
As a whole, current and future massively parallel sequencing
technologies provide a profusion of opportunities that may
expand our understanding of the complex host–pathogen
interaction and improve patient health management. However,
these new technologies will not reach maximal efﬁcacy until
genomics is integrated into microbiological diagnostic labora-
tories, within the healthcare system. Substantial challenges
remain for the development of methods for data analysis and
the harmonization of laboratory procedures. Only under these
circumstances can knowledge developed in the past be
expanded to new genome-based information.
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